News and Media

News and Media

  • Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors

    May 28, 2019

  • Ordinary General Meeting of May 22, 2019

    May 22, 2019

  • Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy

    May 6, 2019

  • Publication of the 2018 Registration Document

    April 8, 2019

  • Ordinary General Meeting on April 26, 2019

    April 5, 2019

  • Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting

    March 25, 2019

  • Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update

    March 12, 2019

  • Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting

    February 13, 2019

  • Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor

    January 3, 2019

  • BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results

    July 27, 2014

  • BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

    April 8, 2014

  • Publication of the 2013 Registration Document

    April 8, 2014

  • BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea

    April 2, 2014

  • BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®

    April 1, 2014

  • BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®

    March 31, 2014

Press Release Signup

Subscribe to receive our Press Releases when they come out.